From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody-drug conjugate development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results